Pancreas

Gastroenterology. 2026;170(1):106-117

Chari ST, Wu B, Lopez C, Lustigova E, Chen Q, Van Den Eeden SK, Leimpeter AD, Fisher W, Wood A, Alexander AS, Valenta J, Vege SS, Carlson EE, Rabe KG, Hart PA, Qian L, Zhao YQ, Yosuf N, Matrisian L, Kenner B, Rinaudo JA, Maitra A, Feng Z

Risk of pancreatic cancer in glycemically defined new-onset diabetes: A prospective cohort study


Background and aims: The increased 3-year incidence of pancreatic cancer after new-onset diabetes observed in retrospective studies needs prospective validation. It is unknown whether incidence varies by race and ethnicity.
Methods: In a prospective, observational study using active real-time surveillance of electronic health records, the authors identified 18,838 adults 50 years or older with glycemically defined new-onset diabetes (GNOD). In this interim analysis, they report 3-year Kaplan-Meier estimates of the proportion diagnosed with pancreatic cancer after GNOD (absolute incidence [95% CI]) and associated standardized incidence ratio (SIR) by race and ethnicity, overall 3-year incidence of pancreatic cancer adjusting for racial distribution of incident diabetes in the United States, and interval between GNOD and pancreatic cancer diagnosis.
Results: During median follow-up of 2.3 years, 82 pancreatic cancers were diagnosed (60% in men; mean [SD] age, 71 [8] years). The 3-year estimates for the proportion diagnosed with pancreatic cancer and associated SIR by race and ethnicity were as follows: non-Hispanic White patients (n = 6518): 0.84% (95% CI: 0.60−1.07) and 6.4 (95% CI: 4.8−8.4); Hispanic patients (n = 5984): 0.40% (95% CI: 0.20−0.60) and 4.2 (95% CI: 2.6−6.3); African American patients (n = 2192): 0.37% (95% CI: 0.07−0.67) and 2.4 (95% CI: 1.0−5.0), and Asian/Pacific Islander patients (n = 3360): 0.22% (95% CI: 0.06−0.39) and 3.0 (95% CI: 1.4−6.0). Overall, race-adjusted 3-year pancreatic cancer incidence was 0.62%. On average, GNOD occurred 8 months before clinical diagnosis (0−4 months in 30.5%, 4−12 months in 31.3%, 12−24 months in 19.5%, and 24−36 months in 18.7%).

Conclusions: GNOD, identifiable in real time using active surveillance of electronic health records, is associated with a high 3-year incidence of pancreatic cancer with marked racial and ethnic differences. Longer-term risk needs further study.

S.T. Chari, Division of Internal Medicine, Department of Gastroenterology, Hepatology and Nutrition, University of Texas MD Anderson Cancer Center, Houston, TX, USA, e-mail: stchari@mdanderson.org

DOI:  10.1053/j.gastro.2025.06.025

Back to overview

this could be of interest: